MATTER Launches Experience Hub in Bengaluru, Strengthens Presence in Karnataka

Electric vehicle innovator MATTER has expanded its footprint in southern India with the launch of a new Experience Hub in Bengaluru, Karnataka. Located at 1st Phase, 1, 100 Feet Ring Road, Vysya Bank Colony in BTM Layout, Bengaluru, the hub offers an interactive retail experience designed to engage customers with the brand’s cutting-edge electric mobility solutions.

Jayanagar MLA C.K. Ramamurthy inaugurated the new Matter Experience hub. The event was attended by MATTER’s senior leadership team, including Co-Founder and Group CDO – Mr. Saran Babu, Lalbhai, Co-Founder and Group COO – Mr. Arun Pratap Singh, Vice President of Sales – Mr. Willy Chengappa, and the dealership principal – Mr Chirag Bafna, along with local dignitaries and industry stakeholders.

At the centre of the new hub is the MATTER AERA, India’s first geared electric motorbike, which has received a strong response from early adopters and EV enthusiasts across the country. The AERA is known for combining performance, design, and sustainability—offering riders a futuristic and powerful alternative to conventional two-wheelers.

The Bengaluru Experience Hub features a 'phygital' format—a blend of physical and digital touchpoints—allowing customers to explore MATTER’s offerings through both guided interactions and self-paced discovery. The space includes technology showcase zones, lifestyle areas, and immersive learning sections aimed at raising awareness and excitement around electric mobility.

Mohal Lalbhai, Founder and CEO of MATTER, said:

"Bengaluru represents the pulse of innovation in India, and our presence here reflects our commitment to making advanced electric mobility accessible to progressive communities. The Experience Hub is more than a showroom — it’s a space for exploration, education, and empowerment, where the future of transportation can be experienced today."

Willy Chengappa, Vice President – Sales, MATTER, commented:

"Karnataka is a key growth market for us. Bengaluru’s vibrant two-wheeler culture makes it an ideal location to bring our flagship product, the AERA, closer to consumers. This new Experience Hub, offers a seamless and engaging customer journey."

Chirag Bafna, Dealer Principal, added:

"We are excited to partner with MATTER to introduce this state-of-the-art Experience Hub to Bengaluru. With the AERA already generating strong interest, we are confident this facility will play a vital role in building a community of electric riders in the region. Our focus will be on delivering exceptional service and a customer-first experience."

With this expansion, MATTER continues to build momentum in its mission to redefine the way Indians experience electric mobility—through innovation, access, and an unwavering focus on the user journey.

 

Three-Year Cancer Remissions Mark Milestone for CAR T-Cell Therapy at Narayana Health City

In a landmark development for cancer care in India, three patients treated with CAR T-cell therapy for relapsed follicular lymphoma at Narayana Health City, Bengaluru, have completed three years of successful follow-up—making this one of the longest documented survivals post-CAR T therapy in South India.

Chimeric Antigen Receptor T-cell (CAR T) therapy, a cutting-edge immunotherapy, has become a beacon of hope for patients with relapsed or treatment-resistant lymphoma. India now produces CAR T therapy domestically, with two CDSCO-approved products—NEXCAR19 and QARTEMI—making this life-saving treatment more accessible and affordable.

Ms. Perumala (name changed), a 66-year-old homemaker, relapsed with aggressive lymphoma in 2022 and underwent CAR T therapy in March 2023. She has since been in complete remission and is now enjoying quality time with her grandchildren. 

Among the long-term survivors is Mr. Rehan (name changed), a 43-year-old from Bengaluru who was diagnosed during the COVID-19 pandemic. After exhausting all conventional therapies, he received CAR T therapy in November 2022. Despite multiple setbacks, including a severe COVID-19 infection and swine flu during his Hajj pilgrimage, he is now in remission and in his third year of follow-up.

India witnesses over 1.4 million new cancer cases annually, with lymphomas accounting for a significant burden among haematological malignancies. While conventional treatments help many patients, relapsed or treatment-resistant cases often have poor survival outcomes. The five-year survival rate for such patients can be as low as 20–30%.

The successful outcomes seen with CAR T-cell therapy, particularly with India’s CDSCO-approved versions like NEXCAR19 and QARTEMI which mark a pivotal opportunity to bridge the survival gap in advanced cancer care. If scaled effectively, this therapy could transform India’s cancer treatment landscape, reducing dependence on overseas options and significantly improving long-term survival rates.

“These cases reflect the transformative potential of CAR T therapy for patients who have exhausted all other options. With this therapy now approved by the Drug Controller General of India (DCGI) and commercially available, Indian patients no longer need to look abroad for advanced treatment,” said Dr. Sharat Damodar, Senior Consultant, Haematologist and Head of Adult BMT at Narayana Health City, Bengaluru and Chairman of the Oncology Collegium at Narayana Health.

The encouraging outcomes observed at Narayana Health City reaffirm the efficacy of CAR T therapy and represent a significant milestone in India’s journey toward advanced cancer care.

“At Narayana Health, we have always believed that the best of global innovation must be made accessible to every Indian. As one of the early pioneers in cancer care and CAR T-cell therapy in the country, we remain committed to staying ahead of the curve with cutting-edge treatments that offer new hope to patients. Our journey is driven by a single purpose — to make world-class care affordable and available to all,” said Dr Devi Prasad Shetty, Chairman and Founder of Narayana Health, Bengaluru.

           

Fenza Exhibitions Pvt. Ltd.'s Asia Labex 2025 – India’s Biggest Laboratory Show Commences in Bengaluru

  Asia Labex 2025, India’s largest and most dedicated exhibition on Laboratory, Analytical, Microbiology, Research, and Biotechnology Instruments, Chemicals, and Consumables, commenced today at the Bangalore International Exhibition Centre (BIEC), Tumkur Road, Neelamangala.

The three-day exhibition was inaugurated by distinguished Guests of Honour Dr. Manoj Kumar Singh, Sr. Vice President – Analytical, Research & Development, Micro Labs Limited, Dr. Ramesh Jagadeesan, Vice President, Reci Pharm Pharmaservices Limited, Dr. Ravindra Vikram Singh, Director & Head – India R&D, Sigma Aldrich (Merck KGaA) and Dr. Nagahanumaiah, Director, Central Manufacturing Technology Institute. 

Sharing insights on the event, Mr. Jaspal Singh, Director, Asia Labex, highlighted that this year’s concurrent Labotica Summit is themed “Science Meets Industry: Bridging the Gap Between Research and Application.” He emphasized that the summit serves as a platform for showcasing futuristic developments in laboratory science, bringing together multi-disciplinary researchers from academia, the pharmaceutical industry, research institutions, and CROs.

He further added that regulatory bodies will present their latest research breakthroughs, contributing to critical discussions on quality control (Q.C.), R&D innovation, and regulatory advancements.

The exhibition covers key focus areas including analytical instrumentation, chromatography, spectroscopy, biotechnology, life sciences, lab consumables, molecular and clinical diagnostics, nanotechnology, filtration, testing and measuring tools, and educational lab equipment.

The concurrent Labotica Summit provides a unique opportunity to engage with visionary speakers and experts driving the future of science and innovation.

.